Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medexus PharmaceuticalsTSX:MDP -1.18%53 EV-to-EBIT is 45.09 as of Jul. 25, 2026, which is 591% above its 10-year median of 6.53. GuruFocus rates TSX:MDP with a GF Score™ of 53/100 and a GF Value™ of C$1.87 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 690 Drug Manufacturers companies, Medexus Pharmaceuticals ranks worse than 84.35% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Medexus Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2026 was C$121.5 Mil.
Medexus Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$4.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medexus Pharmaceuticals EV-to-EBIT Related Terms
Medexus Pharmaceuticals EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medexus Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Medexus Pharmaceuticals's EV-to-EBIT falls into.
Medexus Pharmaceuticals's current Enterprise Value is C$181.7 Mil.
Medexus Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$4.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medexus Pharmaceuticals (TSX:MDP) has a EV-to-EBIT of 45.09 as of Jul. 25, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medexus Pharmaceuticals and its competitors. This is 591% above median its historical median of 6.53. According to the industry distribution chart, Medexus Pharmaceuticals ranks #582 out of 690 companies in the Drug Manufacturers industry, placing it in the top 84.3%.
Is Medexus Pharmaceuticals' EV-to-EBIT too high?
Medexus Pharmaceuticals' current EV-to-EBIT of 45.09 is 591% above median its 10-year median of 6.53. The Drug Manufacturers industry median EV-to-EBIT is 15.46. Medexus Pharmaceuticals' value of 45.09 is 191.7% above this industry median. Based on the distribution chart, Medexus Pharmaceuticals ranks #582 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medexus Pharmaceuticals has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medexus Pharmaceuticals' EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medexus Pharmaceuticals ranks #582 out of 690 companies for EV-to-EBIT. This places Medexus Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBIT is 15.46. Medexus Pharmaceuticals' value of 45.09 is 191.7% above this benchmark. While the company's 10-year median is 6.53 vs. the industry median of 15.46, Medexus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.46, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medexus Pharmaceuticals's current EV-to-EBIT of 45.09 is 191.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medexus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medexus Pharmaceuticals's current EV-to-EBIT is 45.09, which is 591% above median its own 10-year median of 6.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medexus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Medexus Pharmaceuticals (TSX:MDP) is currently considered Significantly Overvalued. The stock's GF Value™ is C$1.87, compared to a current price of C$5.04 — trading 169.5% above its estimated fair value. The current EV-to-EBIT is 45.09, which is 591% above median its 10-year median of 6.53 and 191.7% above the Drug Manufacturers industry median of 15.46. Medexus Pharmaceuticals' overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Medexus Pharmaceuticals (TSX:MDP), the current EV-to-EBIT is 45.09 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medexus Pharmaceuticals (TSX:MDP) Overvalued in 2026?
Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued.
The current stock price of C$5.04 is trading 169.5% above its estimated GF Value™ of C$1.87.
GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for TSX:MDP:
EV-to-EBIT: 45.09 (591% above median its 10-year median of 6.53)
GF Value™: C$1.87 vs. price of C$5.04 (169.5% above fair value)
Industry Position: 191.7% above the Drug Manufacturers median (#582 of 690)
No single metric tells the full story. See the TSX:MDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
53GF Score
Get the complete analysis for TSX:MDP
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:MDP has been successfully added to your 
